{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:29:50Z","timestamp":1788294590363,"version":"build-2803163510"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40265-022-01697-0","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T10:02:47Z","timestamp":1649757767000},"page":"613-631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy"],"prefix":"10.1007","volume":"82","author":[{"given":"Barry","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"issue":"1","key":"1697_CR1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1697_CR2","unstructured":"Surveillance, epidemiology, and end results program. National Cancer Institute. 2021."},{"issue":"20","key":"1697_CR3","first-page":"3043","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood J Am Soc Hematol. 2014;124(20):3043\u201351.","journal-title":"Blood J Am Soc Hematol"},{"issue":"9","key":"1697_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia. 2017;31(9):1915\u201321.","journal-title":"Leukemia"},{"issue":"12","key":"1697_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-018-0155-7","volume":"8","author":"SZ Usmani","year":"2018","unstructured":"Usmani SZ, Hoering A, Cavo M, San-Miguel J, Goldschimdt H, Hajek R, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma\u2014an IMWG Research Project. Blood Cancer J. 2018;8(12):1\u20137.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1697_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","volume":"4","author":"KK Nishimura","year":"2020","unstructured":"Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020;4(2):422\u201331.","journal-title":"Blood Adv"},{"issue":"17","key":"1697_CR7","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","volume":"38","author":"NS Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928\u201337.","journal-title":"J Clin Oncol"},{"key":"1697_CR8","doi-asserted-by":"crossref","unstructured":"Perrot A, Lauwers-Cances V, Cazaubiel T, Facon T, Caillot D, Clement-Filliatre L et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term followup analysis of the IFM 2009 trial. In: Blood. 2020. AMER SOC HEMATOLOGY 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA. 2020.","DOI":"10.1182\/blood-2020-134538"},{"issue":"11","key":"1697_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"S Kumar","year":"2017","unstructured":"Kumar S, Dimopoulos M, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443\u20138.","journal-title":"Leukemia"},{"issue":"5","key":"1697_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/ejh.13046","volume":"100","author":"M Pick","year":"2018","unstructured":"Pick M, Vainstein V, Goldschmidt N, Lavie D, Libster D, Gural A, et al. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD 38 expression and is related to dismal prognosis. Eur J Haematol. 2018;100(5):494\u2013501.","journal-title":"Eur J Haematol"},{"issue":"9","key":"1697_CR11","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375.","journal-title":"Leukemia"},{"key":"1697_CR12","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1182\/blood-2019-124991","volume":"134","author":"LJ Costa","year":"2019","unstructured":"Costa LJ, Hari P, Kumar SK, Tang S, Gandhi UH, Shah JJ, et al. Overall survival of triple class refractory, penta-exposed multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care: a combined analysis of the STORM and Mammoth studies. Blood. 2019;134:3125.","journal-title":"Blood"},{"issue":"2","key":"1697_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252\u201364.","journal-title":"Br J Haematol"},{"issue":"4","key":"1697_CR14","first-page":"220","volume":"1","author":"AG Szabo","year":"2019","unstructured":"Szabo AG, Iversen KF, M\u00f6ller S, Plesner T. The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study. Clin Hematol Int. 2019;1(4):220\u20138.","journal-title":"Clin Hematol Int"},{"key":"1697_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/HS9.0000000000000045","volume":"2","author":"SG Verelst","year":"2018","unstructured":"Verelst SG, Blommestein HM, De Groot S, Gonzalez-McQuire S, DeCosta L, de Raad JB, et al. Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). HemaSphere. 2018;2:4.","journal-title":"HemaSphere"},{"issue":"11","key":"1697_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","volume":"10","author":"C Madry","year":"1998","unstructured":"Madry C, Laabi Y, Callebaut I, Roussel JM, Hatzoglou A, Le-Coniat M, et al. The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol. 1998;10(11):1693\u2013702.","journal-title":"Int Immunol"},{"issue":"25","key":"1697_CR17","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"Y-T Tai","year":"2016","unstructured":"Tai Y-T, Acharya C, An G, Moschetta M, Zhong MY, Feng X, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225\u201336.","journal-title":"Blood"},{"issue":"11","key":"1697_CR18","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-07-0464","volume":"6","author":"MC Ryan","year":"2007","unstructured":"Ryan MC, Hering M, Peckham D, McDonagh CF, Brown L, Kim KM, et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther. 2007;6(11):3009\u201318.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1697_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O'Connor","year":"2004","unstructured":"O\u2019Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199(1):91\u20138.","journal-title":"J Exp Med"},{"issue":"8","key":"1697_CR20","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048\u201360.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1697_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI18025","volume":"112","author":"DT Avery","year":"2003","unstructured":"Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Investig. 2003;112(2):286\u201397.","journal-title":"J Clin Investig"},{"issue":"6","key":"1697_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bjh.14145","volume":"174","author":"L Lee","year":"2016","unstructured":"Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016;174(6):911\u201322.","journal-title":"Br J Haematol"},{"issue":"9","key":"1697_CR23","first-page":"1336","volume":"123","author":"I Frigyesi","year":"2014","unstructured":"Frigyesi I, Adolfsson J, Ali M, Kronborg-Christophersen M, Johnsson E, Turesson I, et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood J Am Soc Hematol. 2014;123(9):1336\u201340.","journal-title":"Blood J Am Soc Hematol"},{"key":"1697_CR24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"S-F Cho","year":"2018","unstructured":"Cho S-F, Anderson KC, Tai Y-T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.","journal-title":"Front Immunol"},{"issue":"2","key":"1697_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103(2):689\u201394.","journal-title":"Blood"},{"issue":"12","key":"1697_CR26","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","volume":"21","author":"S Xu","year":"2001","unstructured":"Xu S, Lam K-P. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol. 2001;21(12):4067\u201374.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"1697_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-0337-y","volume":"10","author":"A Dogan","year":"2020","unstructured":"Dogan A, Siegel D, Tran N, Fu A, Fowler J, Belani R, et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J. 2020;10(6):1\u201313.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1697_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158(6):727\u201338.","journal-title":"Br J Haematol"},{"issue":"6","key":"1697_CR29","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1021\/bi048227k","volume":"44","author":"ES Day","year":"2005","unstructured":"Day ES, Cachero TG, Qian F, Sun Y, Wen D, Pelletier M, et al. Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA. Biochemistry. 2005;44(6):1919\u201331.","journal-title":"Biochemistry"},{"issue":"4","key":"1697_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00277-013-1924-9","volume":"93","author":"L Bolkun","year":"2014","unstructured":"Bolkun L, Lemancewicz D, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, et al. BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. Ann Hematol. 2014;93(4):635\u201344.","journal-title":"Ann Hematol"},{"issue":"3","key":"1697_CR31","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3892\/ol.2017.6528","volume":"14","author":"J Pan","year":"2017","unstructured":"Pan J, Sun Y, Zhang N, Li J, Ta F, Wei W, et al. Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance. Oncol Lett. 2017;14(3):2657\u201362.","journal-title":"Oncol Lett"},{"issue":"8","key":"1697_CR32","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","volume":"103","author":"J Moreaux","year":"2004","unstructured":"Moreaux J, Legouffe E, Jourdan E, Quittet P, R\u00e8me T, Lugagne C, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103(8):3148\u201357.","journal-title":"Blood"},{"issue":"9","key":"1697_CR33","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00277-012-1470-x","volume":"91","author":"M Fragioudaki","year":"2012","unstructured":"Fragioudaki M, Boula A, Tsirakis G, Psarakis F, Spanoudakis M, Papadakis I, et al. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann Hematol. 2012;91(9):1413\u20138.","journal-title":"Ann Hematol"},{"issue":"3","key":"1697_CR34","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","volume":"165","author":"A Hatzoglou","year":"2000","unstructured":"Hatzoglou A, Roussel J, Bourgeade M-F, Rogier E, Madry C, Inoue J, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-\u03baB, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol. 2000;165(3):1322\u201330.","journal-title":"J Immunol"},{"issue":"2","key":"1697_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/cbf.3169","volume":"34","author":"X Shen","year":"2016","unstructured":"Shen X, Guo Y, Qi J, Shi W, Wu X, Ju S. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways. Cell Biochem Funct. 2016;34(2):104\u201310.","journal-title":"Cell Biochem Funct"},{"key":"1697_CR36","first-page":"2","volume":"2021","author":"YR Miao","year":"2021","unstructured":"Miao YR, Cenik C, Jiang D, Mizuno K, Li GC, Zhao H, et al. Aberrant BCMA signaling promotes tumor growth by altering protein translation machinery, a therapeutic target for the treatment of relapse\/refractory multiple myeloma. bioRxiv. 2021;2021:2.","journal-title":"bioRxiv"},{"issue":"1","key":"1697_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn P-H, Cheng Q, Chu Y, Schmidt-Supprian M, et al. \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6(1):1\u201312.","journal-title":"Nat Commun"},{"issue":"9","key":"1697_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.it.2018.07.002","volume":"39","author":"E Meinl","year":"2018","unstructured":"Meinl E, Thaler FS, Lichtenthaler SF. Shedding of BAFF\/APRIL receptors controls B cells. Trends Immunol. 2018;39(9):673\u20136.","journal-title":"Trends Immunol"},{"issue":"4","key":"1697_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","volume":"102","author":"M Ghermezi","year":"2017","unstructured":"Ghermezi M, Li M, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785.","journal-title":"Haematologica"},{"issue":"13","key":"1697_CR40","first-page":"1688","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood J Am Soc Hematol. 2016;128(13):1688\u2013700.","journal-title":"Blood J Am Soc Hematol"},{"key":"1697_CR41","doi-asserted-by":"crossref","unstructured":"Bujarski S, Udd K, Soof C, Spektor TM, Safaie T, Chen H et al. Baseline and increases in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among relapsed\/refractory multiple myeloma patients undergoing new treatments. In: 2019, American Society of Hematology Washington, DC. 2019.","DOI":"10.1182\/blood-2019-132012"},{"key":"1697_CR42","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","volume":"81","author":"H Chen","year":"2019","unstructured":"Chen H, Li M, Xu N, Ng N, Sanchez E, Soof CM, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 2019;81:62\u20136.","journal-title":"Leuk Res"},{"issue":"6","key":"1697_CR43","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma. J Clin Investig. 2019;129(6):2210\u201321.","journal-title":"J Clin Investig"},{"issue":"3","key":"1697_CR44","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","volume":"33","author":"K Kinneer","year":"2019","unstructured":"Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, et al. Preclinical assessment of an antibody\u2013PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. Leukemia. 2019;33(3):766\u201371.","journal-title":"Leukemia"},{"issue":"12","key":"1697_CR45","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641\u201353.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1697_CR46","first-page":"1585","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, et al. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood J Am Soc Hematol. 2019;134(19):1585\u201397.","journal-title":"Blood J Am Soc Hematol"},{"key":"1697_CR47","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Pont M, Sather BD, Turtle CJ, Till BG, Nagengast AM et al. Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma. In: 2019, American Society of Hematology Washington, DC. 2019.","DOI":"10.1182\/blood-2019-129405"},{"key":"1697_CR48","doi-asserted-by":"crossref","unstructured":"Kumar S, Migkou M, Bhutani M, Spencer A, Ailawadhi S, Kalff A et al. Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed\/refractory multiple myeloma. In: Proceedings of the 62nd ASH annual Meeting and Exposition, San Diego, CA, USA. 2020.","DOI":"10.1182\/blood-2020-136375"},{"issue":"2","key":"1697_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.blre.2014.09.011","volume":"29","author":"DW Sherbenou","year":"2015","unstructured":"Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B. The development of potential antibody-based therapies for myeloma. Blood Rev. 2015;29(2):81\u201391.","journal-title":"Blood Rev"},{"issue":"4","key":"1697_CR50","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"key":"1697_CR51","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3389\/fimmu.2020.01155","volume":"11","author":"WSC Bruins","year":"2020","unstructured":"Bruins WSC, Zweegman S, Mutis T, van de Donk N. Targeted therapy with immunoconjugates for multiple myeloma. Front Immunol. 2020;11:1155.","journal-title":"Front Immunol"},{"key":"1697_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","volume":"30","author":"A Pahl","year":"2018","unstructured":"Pahl A, Lutz C, Hechler T. Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol. 2018;30:85\u20139.","journal-title":"Drug Discov Today Technol"},{"key":"1697_CR53","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/biom10101387","volume":"10","author":"TK Bera","year":"2020","unstructured":"Bera TK. Anti-BCMA immunotoxins: design, production, and preclinical evaluation. Biomolecules. 2020;10:10.","journal-title":"Biomolecules"},{"issue":"2","key":"1697_CR54","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","volume":"17","author":"JR McCombs","year":"2015","unstructured":"McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. Aaps j. 2015;17(2):339\u201351.","journal-title":"Aaps j"},{"issue":"20","key":"1697_CR55","first-page":"3128","volume":"123","author":"Y-T Tai","year":"2014","unstructured":"Tai Y-T, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti\u2013B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood J Am Soc Hematol. 2014;123(20):3128\u201338.","journal-title":"Blood J Am Soc Hematol"},{"issue":"15","key":"1697_CR56","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Belantamab mafodotin: first approval. Drugs. 2020;80(15):1607\u201313.","journal-title":"Drugs"},{"key":"1697_CR57","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1182\/blood-2019-123705","volume":"134","author":"S Eastman","year":"2019","unstructured":"Eastman S, Shelton C, Gupta I, Krueger J, Blackwell C, Bojczuk PM. Synergistic activity of belantamab mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-expressing cancer cell lines. Blood. 2019;134:4401.","journal-title":"Blood"},{"issue":"10","key":"1697_CR58","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","volume":"20","author":"RM de Oca","year":"2021","unstructured":"de Oca RM, Alavi AS, Vitali N, Bhattacharya S, Blackwell C, Patel K, et al. Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo. Mol Cancer Ther. 2021;20(10):1941\u201355.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1697_CR59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","volume":"9","author":"S Trudel","year":"2019","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37.","journal-title":"Blood Cancer J"},{"issue":"22","key":"1697_CR60","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1002\/cncr.33809","volume":"127","author":"S Lonial","year":"2021","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021;127(22):4198\u2013212.","journal-title":"Cancer"},{"issue":"2","key":"1697_CR61","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207\u201321.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1697_CR62","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-020-00369-0","volume":"10","author":"PG Richardson","year":"2020","unstructured":"Richardson PG, Lee HC, Abdallah AO, Cohen AD, Kapoor P, Voorhees PM, et al. Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J. 2020;10(10):106.","journal-title":"Blood Cancer J"},{"key":"1697_CR63","first-page":"11","volume":"2021","author":"A Wahab","year":"2021","unstructured":"Wahab A, Rafae A, Mushtaq K, Masood A, Ehsan H, Khakwani M, et al. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol. 2021;2021:11.","journal-title":"Front Oncol"},{"issue":"16","key":"1697_CR64","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2217\/fon-2020-1269","volume":"17","author":"AK Nooka","year":"2021","unstructured":"Nooka AK, Weisel K, van de Donk NW, Routledge D, Otero PR, Song K, et al. Belantamab mafodotin in combination with novel agents in relapsed\/refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021;17(16):1987\u20132003.","journal-title":"Future Oncol"},{"key":"1697_CR65","doi-asserted-by":"crossref","unstructured":"De Oca RM, Gupta I, Shelton C. Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and\/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma. In: 2020, AACR. 2020.","DOI":"10.1158\/1538-7445.AM2020-6711"},{"key":"1697_CR66","doi-asserted-by":"crossref","unstructured":"Popat R, Nooka A, Stockerl-Goldstein K, Abonour R, Ramaekers R, Khot A et al., DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib\/dexamethasone (BorDex) in relapsed\/refractory multiple myeloma (RRMM). In: 2020, American Society of Hematology Washington, DC. 2020.","DOI":"10.1182\/blood-2020-139332"},{"issue":"15","key":"1697_CR67","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1200\/JCO.2020.38.15_suppl.8502","volume":"38","author":"AK Nooka","year":"2020","unstructured":"Nooka AK, Stockerl-Goldstein K, Quach H, Forbes A, Mateos M-V, Khot A, et al. DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib\/dexamethasone in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2020;38(15):8502\u20138502.","journal-title":"J Clin Oncol"},{"key":"1697_CR68","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-139785","volume":"136","author":"S Trudel","year":"2020","unstructured":"Trudel S, Davis R, Lewis NM, Bakshi KK, Chopra B, de Oca RM, et al. DREAMM-8: a phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2020;136:4.","journal-title":"Blood"},{"key":"1697_CR69","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1182\/blood-2021-147101","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, McCurdy A, Sutherland HJ, Louzada ML, Venner CP, Mian HS, et al. Part 1 results of a dose-finding study of belantamab mafodotin in combination with pomalidomide and dexamethasone for the treatment of relapsed\/refractory multiple myeloma (RRMM). Blood. 2021;138:1653.","journal-title":"Blood"},{"key":"1697_CR70","doi-asserted-by":"crossref","unstructured":"Trudel SMA, Sutherland HJ et al. Part 1 results of a dose-finding study of belantamab mafodotin (GSK2857916) in combination with pomalidomide and dexamethasone for the treatment of relapsed\/refractory multiple myeloma. In: 2020 ASH Annual Meeting and Exposition. 2020.","DOI":"10.1182\/blood-2021-147101"},{"key":"1697_CR71","doi-asserted-by":"crossref","unstructured":"Weisel K, Hopkins TG, Fecteau D, Bao W, Quigley C, Jewell RC et al. Dreamm-3: a phase 3, open-label, randomized study to evaluate the efficacy and safety of belantamab mafodotin (GSK2857916) monotherapy compared with pomalidomide plus low-dose dexamethasone (Pom\/Dex) in participants with relapsed\/refractory multiple myeloma (RRMM). In: 2019, American Society of Hematology Washington, DC. 2019.","DOI":"10.1182\/blood-2019-129893"},{"key":"1697_CR72","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Terpos E, Janowski W, Quach H, West S, Williams D et al. DREAMM-9: Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM). In: 2020, American Society of Clinical Oncology. 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8556"},{"issue":"Supplement 1","key":"1697_CR73","first-page":"3153","volume":"130","author":"K Kinneer","year":"2017","unstructured":"Kinneer K, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, et al. Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma. Blood. 2017;130(Supplement 1):3153\u20133153.","journal-title":"Blood"},{"issue":"10","key":"1697_CR74","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/j.clml.2019.09.257","volume":"19","author":"Y-T Tai","year":"2019","unstructured":"Tai Y-T, Xing L, Lin L, Yu T, Cho S-F, Wen K, et al. MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(10):e154\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1697_CR75","unstructured":"Taylor NP. AstraZeneca drops BCMA drug after seeing early clinical data. In: 2021, Questex LLC: Fierce Biotech. 2021."},{"key":"1697_CR76","volume-title":"Antibody-maytansinoid conjugates for the treatment of myeloma in MAbs","author":"RJ Lutz","year":"2009","unstructured":"Lutz RJ, Whiteman KR. Antibody-maytansinoid conjugates for the treatment of myeloma in MAbs. Hoboken: Taylor & Francis; 2009."},{"issue":"10","key":"1697_CR77","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/bmt.2010.300","volume":"46","author":"S Thiant","year":"2011","unstructured":"Thiant S, Labalette M, Trauet J, Coiteux V, De Berranger E, Dessaint J, et al. Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant. 2011;46(10):1374\u201381.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1697_CR78","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","volume":"20","author":"V Figueroa-Vazquez","year":"2021","unstructured":"Figueroa-Vazquez V, Ko J, Breunig C, Baumann A, Giesen N, P\u00e1lfi A, et al. HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2021;20(2):367\u201378.","journal-title":"Mol Cancer Ther"},{"issue":"Supplement 1","key":"1697_CR79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2020-142285","volume":"136","author":"A Strassz","year":"2020","unstructured":"Strassz A, Raab MS, Orlowski RZ, Kulke M, Schiedner G, Pahl A. A first in human study planned to evaluate Hdp-101, an Anti-BCMA Amanitin antibody-drug conjugate with a new payload and a new mode of action, in multiple myeloma. Blood. 2020;136(Supplement 1):34\u201334.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1697_CR80","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1182\/blood-2018-99-118412","volume":"132","author":"RK Singh","year":"2018","unstructured":"Singh RK, Jones RJ, Hong S, Shirazi F, Wang H, Kuiatse I, et al. HDP101, a Novel B-cell maturation antigen (BCMA)-targeted antibody conjugated to \u03b1-amanitin, is active against myeloma with preferential efficacy against pre-clinical models of deletion 17p. Blood. 2018;132(Supplement 1):593\u2013593.","journal-title":"Blood"},{"key":"1697_CR81","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","volume":"8","author":"G Fan","year":"2015","unstructured":"Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8:130.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1697_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):1\u201314.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1697_CR83","first-page":"188","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood J Am Soc Hematol. 2014;124(2):188\u201395.","journal-title":"Blood J Am Soc Hematol"},{"key":"1697_CR84","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","volume":"15","author":"LL Riegler","year":"2019","unstructured":"Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;15:323.","journal-title":"Ther Clin Risk Manag"},{"key":"1697_CR85","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433\u201344.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"1697_CR86","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17474086.2019.1585238","volume":"12","author":"UH Acharya","year":"2019","unstructured":"Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, et al. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 2019;12(3):195\u2013205.","journal-title":"Expert Rev Hematol"},{"key":"1697_CR87","first-page":"1","volume":"2021","author":"EC Morris","year":"2021","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Rev Immunol. 2021;2021:1\u201312.","journal-title":"Nature Rev Immunol"},{"issue":"12","key":"1697_CR88","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404\u201319.","journal-title":"Cancer Discov"},{"key":"1697_CR89","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.HS9.0000558628.70462.93","volume":"3","author":"JG Borrega","year":"2019","unstructured":"Borrega JG, G\u00f6del P, R\u00fcger MA, Onur \u00d6A, Shimabukuro-Vornhagen A, Kochanek M, et al. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere. 2019;3:2.","journal-title":"Hemasphere"},{"key":"1697_CR90","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2147\/JBM.S281247","volume":"12","author":"O Castaneda-Puglianini","year":"2021","unstructured":"Castaneda-Puglianini O, Chavez JC. Assessing and management of neurotoxicity after CAR-T therapy in diffuse large B-Cell lymphoma. J Blood Med. 2021;12:775.","journal-title":"J Blood Med"},{"issue":"8","key":"1697_CR91","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38(8):775\u201383.","journal-title":"J Clin Oncol"},{"key":"1697_CR92","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","volume":"11","author":"M Lejeune","year":"2020","unstructured":"Lejeune M, K\u00f6se MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. Front Immunol. 2020;11:762.","journal-title":"Front Immunol"},{"key":"1697_CR93","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood-2018-99-118425","volume":"132","author":"S-F Cho","year":"2018","unstructured":"Cho S-F, Lin L, Xing L, Liu J, Yu T, Wen K, et al. Anti-BCMA BiTE\u00ae AMG 701 potently induces specific T cell lysis of human multiple myeloma (MM) cells and immunomodulation in the bone marrow microenvironment. Blood. 2018;132:592.","journal-title":"Blood"},{"key":"1697_CR94","doi-asserted-by":"crossref","unstructured":"Harrison SJ, Minnema MC, Lee HC, Spencer A, Kapoor P, Madduri D et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE (R)(bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM). in Blood. In: 2020. AMER SOC HEMATOLOGY 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA. 2020.","DOI":"10.1182\/blood-2020-134063"},{"issue":"3","key":"1697_CR95","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","volume":"31","author":"A Seckinger","year":"2017","unstructured":"Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396\u2013410.","journal-title":"Cancer Cell"},{"key":"1697_CR96","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood-2019-122895","volume":"134","author":"LJ Costa","year":"2019","unstructured":"Costa LJ, Wong SW, Berm\u00fadez A, de la Rubia J, Mateos M-V, Ocio EM, et al. First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134:143\u2013143.","journal-title":"Blood"},{"issue":"18","key":"1697_CR97","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, et al. Teclistamab is an active T cell\u2013redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4(18):4538\u201349.","journal-title":"Blood Adv"},{"issue":"15","key":"1697_CR98","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1200\/JCO.2020.38.15_suppl.100","volume":"38","author":"SZ Usmani","year":"2020","unstructured":"Usmani SZ, Mateos M-V, Nahi H, Krishnan AY, Donk NWCJVD, Miguel JS, et al. Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (R\/R MM). J Clin Oncol. 2020;38(15):100.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1697_CR99","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1200\/JCO.2021.39.15_suppl.8007","volume":"39","author":"AY Krishnan","year":"2021","unstructured":"Krishnan AY, Garfall AL, Mateos M-V, Donk NWCJVD, Nahi H, San-Miguel JF, et al. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in relapsed\/refractory multiple myeloma (MM). J Clin Oncol. 2021;39(15):8007.","journal-title":"J Clin Oncol"},{"issue":"10301","key":"1697_CR100","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NW, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen\u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. The Lancet. 2021;398(10301):665\u201374.","journal-title":"The Lancet"},{"key":"1697_CR101","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2021-147915","volume":"138","author":"P Moreau","year":"2021","unstructured":"Moreau P, Usmani SZ, Garfall AL, van de Donk NW, Nahi H, San-Miguel J, et al. Updated results from majesTEC-1: phase 1\/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed\/refractory multiple myeloma. Blood. 2021;138:896.","journal-title":"Blood"},{"issue":"1","key":"1697_CR102","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1182\/blood-2019-121805","volume":"134","author":"NS Raje","year":"2019","unstructured":"Raje NS, Jakubowiak A, Gasparetto C, Cornell RF, Krupka HI, Navarro D, et al. Safety, Clinical activity, pharmacokinetics, and pharmacodynamics from a phase I study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2019;134(1):1869\u20131869.","journal-title":"Blood"},{"key":"1697_CR103","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1182\/blood-2018-99-110427","volume":"132","author":"AM Lesokhin","year":"2018","unstructured":"Lesokhin AM, Raje N, Gasparetto CJ, Walker J, Krupka HI, Joh T, et al. A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen\/CD3 bispecific antibody, in patients with relapsed\/refractory advanced multiple myeloma. Blood. 2018;132:3229.","journal-title":"Blood"},{"issue":"15","key":"1697_CR104","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2021.39.15_suppl.8006","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Raje NS, Costello C, Dholaria BR, Solh MM, Levy MY, et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). J Clin Oncol. 2021;39(15):8006\u20138006.","journal-title":"J Clin Oncol"},{"key":"1697_CR105","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2021-150519","volume":"138","author":"M Sebag","year":"2021","unstructured":"Sebag M, Raje NS, Bahlis NJ, Costello C, Dholaria B, Solh M, et al. Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from magnetismm-1. Blood. 2021;138:895.","journal-title":"Blood"},{"key":"1697_CR106","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","volume":"11","author":"C Caraccio","year":"2020","unstructured":"Caraccio C, Krishna S, Phillips DJ, Sch\u00fcrch CM. Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions. Front Immunol. 2020;11:501.","journal-title":"Front Immunol"},{"issue":"5","key":"1697_CR107","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","volume":"5","author":"DJ DiLillo","year":"2021","unstructured":"DiLillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, et al. A BCMAxCD3 bispecific T cell\u2013engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021;5(5):1291\u2013304.","journal-title":"Blood Adv"},{"key":"1697_CR108","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1182\/blood-2018-99-112500","volume":"132","author":"DJ Dilillo","year":"2018","unstructured":"Dilillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, et al. REGN5458, a bispecific BCMAxCD3 T cell engaging antibody, demonstrates robust in vitro and in vivo anti-tumor efficacy in multiple myeloma models, comparable to that of BCMA CAR T cells. Blood. 2018;132:1944.","journal-title":"Blood"},{"key":"1697_CR109","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1182\/blood-2021-144921","volume":"138","author":"JA Zonder","year":"2021","unstructured":"Zonder JA, Richter J, Bumma N, Brayer J, Hoffman JE, Bensinger WI, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2021;138:160.","journal-title":"Blood"},{"issue":"15","key":"1697_CR110","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.1200\/JCO.2018.36.15_suppl.8034","volume":"36","author":"B Buelow","year":"2018","unstructured":"Buelow B, Choudry P, Clarke S, Dang K, Davison L, Aldred SF, et al. Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma. J Clin Oncol. 2018;36(15):8034\u20138034.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1697_CR111","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-139893","volume":"136","author":"C Rodriguez","year":"2020","unstructured":"Rodriguez C, D\u2019Souza A, Shah N, Voorhees PM, Buelow B, Vij R, et al. Initial results of a phase I study of TNB-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in relapsed\/refractory multiple myeloma. Blood. 2020;136(Supplement 1):43\u20134.","journal-title":"Blood"},{"key":"1697_CR112","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood-2021-150757","volume":"138","author":"S Kumar","year":"2021","unstructured":"Kumar S, D\u2019Souza A, Shah N, Rodriguez C, Voorhees PM, Bueno OF, et al. A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138:900.","journal-title":"Blood"},{"key":"1697_CR113","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, et al. CAR-T design: elements and their synergistic function. EBioMedicine. 2020;58:102931.","journal-title":"EBioMedicine"},{"issue":"4","key":"1697_CR114","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388\u201398.","journal-title":"Cancer Discov"},{"issue":"6","key":"1697_CR115","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"NW van de Donk","year":"2021","unstructured":"van de Donk NW, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446\u201361.","journal-title":"Lancet Haematol"},{"issue":"3","key":"1697_CR116","first-page":"696","volume":"119","author":"D-G Song","year":"2012","unstructured":"Song D-G, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood J Am Soc Hematol. 2012;119(3):696\u2013706.","journal-title":"Blood J Am Soc Hematol"},{"issue":"3","key":"1697_CR117","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1697_CR118","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci. 1993;90(2):720\u20134.","journal-title":"Proc Natl Acad Sci"},{"issue":"24","key":"1697_CR119","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","volume":"130","author":"L Mikkilineni","year":"2017","unstructured":"Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017;130(24):2594\u2013602.","journal-title":"Blood"},{"key":"1697_CR120","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Therapy-Oncol. 2016;3:16011.","journal-title":"Mol Therapy-Oncol"},{"issue":"6","key":"1697_CR121","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","volume":"20","author":"M-R Benmebarek","year":"2019","unstructured":"Benmebarek M-R, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20(6):1283.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1697_CR122","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/1078-0432.CCR-18-1211","volume":"25","author":"CM Suryadevara","year":"2019","unstructured":"Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, et al. Preventing lck activation in CAR T cells confers Treg resistance but requires 4\u20131BB signaling for them to persist and treat solid tumors in nonlymphodepleted hosts. Clin Cancer Res. 2019;25(1):358\u201368.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1697_CR123","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907\u201312.","journal-title":"J Exp Med"},{"key":"1697_CR124","doi-asserted-by":"publisher","first-page":"251513552092716","DOI":"10.1177\/2515135520927164","volume":"8","author":"L Halim","year":"2020","unstructured":"Halim L, Maher J. CAR T-cell immunotherapy of B-cell malignancy: the story so far. Therapeut Adv Vaccines Immunotherapy. 2020;8:2515135520927164.","journal-title":"Therapeut Adv Vaccines Immunotherapy"},{"issue":"4","key":"1697_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):1\u201318.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1697_CR126","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"KM Friedman","year":"2018","unstructured":"Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, et al. Effective targeting of multiple B-cell maturation antigen\u2013expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther. 2018;29(5):585\u2013601.","journal-title":"Hum Gene Ther"},{"issue":"40","key":"1697_CR127","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.18632\/oncotarget.25359","volume":"9","author":"D-X Bu","year":"2018","unstructured":"Bu D-X, Singh R, Choi EE, Ruella M, Nunez-Cruz S, Mansfield KG, et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018;9(40):25764.","journal-title":"Oncotarget"},{"issue":"2","key":"1697_CR128","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"CF de Larrea","year":"2020","unstructured":"de Larrea CF, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma. Blood Cancer Discov. 2020;1(2):146.","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"1697_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13(1):1\u201314.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1697_CR130","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1182\/hematology.2020000111","volume":"2020","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn K, Mailankody S, Smith EL. Future of CAR T cells in multiple myeloma. Hematology 2014, the American Society of Hematology Education Program Book. Hematology. 2020;2020(1):272\u20139.","journal-title":"Hematology"},{"key":"1697_CR131","doi-asserted-by":"crossref","unstructured":"Garfall AL, Cohen AD, Lacey SF, Tian L, Hwang W-T, Vogl DT et al. Combination anti-Bcma and anti-CD19 CAR T cells as consolidation of response to prior therapy in multiple myeloma. In: 2019, American Society of Hematology Washington, DC. 2019.","DOI":"10.1182\/blood-2019-131515"},{"issue":"10","key":"1697_CR132","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019;6(10):e521\u20139.","journal-title":"Lancet Haematol"},{"key":"1697_CR133","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","volume":"1","author":"S Simon","year":"2020","unstructured":"Simon S, Riddell SR. Dual targeting with CAR T cells to limit antigen escape in multiple myeloma. Blood Cancer Discov. 2020;1:130\u20135.","journal-title":"Blood Cancer Discov"},{"issue":"18","key":"1697_CR134","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"N Engl J Med"},{"issue":"8","key":"1697_CR135","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"15","key":"1697_CR136","first-page":"8016","volume":"39","author":"D Larry","year":"2021","unstructured":"Larry D, Anderson J, Munshi NC, Shah N, Jagannath S, Berdeja JG, Lonial S, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results. J Clin Oncol. 2021;39(15):8016\u20138016.","journal-title":"J Clin Oncol"},{"key":"1697_CR137","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Berdeja JG, Truppel-Hartmann A, Fei Y, Wortman-Vayn H, Shelat S et al. KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma. Wolters Kluwer Health. 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053"},{"key":"1697_CR138","doi-asserted-by":"publisher","first-page":"204062072110196","DOI":"10.1177\/20406207211019622","volume":"12","author":"A Oriol","year":"2021","unstructured":"Oriol A, Abril L, Torrent A, Ibarra G, Ribera J-M. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Therapeut Adv Hematol. 2021;12:20406207211019624.","journal-title":"Therapeut Adv Hematol"},{"key":"1697_CR139","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-137156","volume":"136","author":"M Delforge","year":"2020","unstructured":"Delforge M, Baz RC, Cavo M, Callander NS, Ghobadi A, Rodriguez-Otero P, et al. KarMMa-3: a phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma. Blood. 2020;136:24\u20135.","journal-title":"Blood"},{"key":"1697_CR140","doi-asserted-by":"crossref","unstructured":"Alsina M, Shah N, Raje NS, Jagannath S, Madduri D, Kaufman JL et al. Updated results from the phase I CRB-402 study of anti-BCMA CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: correlation of expansion and duration of response with T cell phenotypes. In: Blood. Amer Soc Hematology 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA. 2020.","DOI":"10.1182\/blood-2020-140410"},{"key":"1697_CR141","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Alsina M, Shah ND, Siegel DS, Jagannath S, Madduri D et al. Updated results from an ongoing phase 1 clinical study of bb21217 anti-Bcma CAR T cell therapy. In: 2019, American Society of Hematology Washington, DC. 2019.","DOI":"10.1182\/blood-2019-126660"},{"key":"1697_CR142","doi-asserted-by":"crossref","unstructured":"Finney OC, Yeri A, Mao P, Pandya C, Alonzo E, Hopkins G et al. Molecular and phenotypic profiling of drug product and post-infusion samples from CRB-402, an ongoing: phase I Clinical Study of bb21217 a BCMA-directed CAR T cell therapy. In: Blood. Amer Soc Hematology 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA. 2020.","DOI":"10.1182\/blood-2020-142426"},{"issue":"19","key":"1697_CR143","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen L-J, Yang S-S, Sun Y, Wu W, Liu Y-F, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci. 2019;116(19):9543\u201351.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1697_CR144","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.","journal-title":"J Hematol Oncol"},{"key":"1697_CR145","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/blood-2021-146060","volume":"138","author":"T Martin","year":"2021","unstructured":"Martin T, Usmani SZ, Berdeja JG, Jakubowiak A, Agha M, Cohen AD, et al. Updated results from CARTITUDE-1: phase 1b\/2Study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138:549.","journal-title":"Blood"},{"key":"1697_CR146","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/blood-2021-146200","volume":"138","author":"M-V Mateos","year":"2021","unstructured":"Mateos M-V, Weisel K, Martin T, Berdeja JG, Jakubowiak A, Stewart AK, et al. Ciltacabtagene autoleucel for triple-class exposed multiple myeloma: adjusted comparisons of CARTITUDE-1 patient outcomes versus therapies from real-world clinical practice from the locommotion prospective study. Blood. 2021;138:550.","journal-title":"Blood"},{"issue":"10297","key":"1697_CR147","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. The Lancet. 2021;398(10297):314\u201324.","journal-title":"The Lancet"},{"key":"1697_CR148","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1182\/blood-2021-146072","volume":"138","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Cohen AD, Delforge M, Hillengass J, Goldschmidt H, Weisel K, et al. Efficacy and safety of ciltacabtagene autoleucel (Cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1\u20133 prior lines of therapy: updated results from CARTITUDE-2. Blood. 2021;138:3866.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1697_CR149","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","volume":"132","author":"S Mailankody","year":"2018","unstructured":"Mailankody S, Htut M, Lee KP, Bensinger W, Devries T, Piasecki J, et al. JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE). Blood. 2018;132(Supplement 1):957\u2013957.","journal-title":"Blood"},{"key":"1697_CR150","doi-asserted-by":"crossref","unstructured":"Mailankody S, Jakubowiak AJ, Htut M, Costa LJ, Lee K, Ganguly S, et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011). American Society of Clinical Oncology. 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.8504"},{"key":"1697_CR151","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/JEP.S265288","volume":"13","author":"M Offidani","year":"2021","unstructured":"Offidani M, Corvatta L, Mor\u00e8 S, Olivieri A. Novel experimental drugs for treatment of multiple myeloma. J Exp Pharmacol. 2021;13:245.","journal-title":"J Exp Pharmacol"},{"key":"1697_CR152","doi-asserted-by":"crossref","unstructured":"Hao S, Jin J, Jiang S, Li Z, Zhang W, Yang M et al. Two-year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human anti-Bcma CAR T Cells (CT053) in relapsed\/refractory multiple myeloma. In: Blood. Amer Soc Hematology 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA. 2020.","DOI":"10.1182\/blood-2020-140156"},{"key":"1697_CR153","doi-asserted-by":"crossref","unstructured":"Jie J, Hao S, Jiang S, Li Z, Yang M, Zhang W et al. Phase 1 trial of the safety and efficacy of fully human anti-Bcma CAR T cells in relapsed\/refractory multiple myeloma. In: 2019, American Society of Hematology Washington, DC. 2019.","DOI":"10.1182\/blood-2019-126104"},{"key":"1697_CR154","doi-asserted-by":"crossref","unstructured":"Mailankody S, Ghosh A, Staehr M, Purdon TJ, Roshal M, Halton E et al. Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial. In: 2018, Am Soc Hematology. 2018.","DOI":"10.1182\/blood-2018-99-119717"},{"issue":"2","key":"1697_CR155","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/leu.2016.211","volume":"31","author":"B Paiva","year":"2017","unstructured":"Paiva B, Puig N, Cedena M-T, de Jong BG, Ruiz Y, Rapado I, et al. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia. 2017;31(2):382\u201392.","journal-title":"Leukemia"},{"issue":"6","key":"1697_CR156","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","volume":"103","author":"W Matsui","year":"2004","unstructured":"Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332\u20136.","journal-title":"Blood"},{"issue":"1","key":"1697_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-020-00192-6","volume":"8","author":"L Kang","year":"2020","unstructured":"Kang L, Zhang J, Li M, Xu N, Qi W, Tan J, et al. Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma. Biomark Res. 2020;8(1):1\u201311.","journal-title":"Biomark Res"},{"key":"1697_CR158","doi-asserted-by":"crossref","unstructured":"Zhang H, Gao L, Liu L, Wang J, Wang S, Gao L et al. A Bcma and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma. In: 2019, American Society of Hematology Washington, DC. 2019.","DOI":"10.1182\/blood-2019-131056"},{"key":"1697_CR159","doi-asserted-by":"crossref","unstructured":"Li C, Mei H, Hu Y, Guo T, Liu L, Jiang H et al. A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed\/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial. In: 2019, American Society of Hematology Washington, DC. 2019.","DOI":"10.1182\/blood-2019-130340"},{"issue":"3","key":"1697_CR160","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp S, Mufti G, Poirot L. \u2018Off-the-shelf\u2019allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1697_CR161","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/cells7100155","volume":"7","author":"C Graham","year":"2018","unstructured":"Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic CAR-T cells: more than ease of access? Cells. 2018;7(10):155.","journal-title":"Cells"},{"issue":"6","key":"1697_CR162","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","volume":"27","author":"C Sommer","year":"2019","unstructured":"Sommer C, Boldajipour B, Kuo TC, Bentley T, Sutton J, Chen A, et al. Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma. Mol Ther. 2019;27(6):1126\u201338.","journal-title":"Mol Ther"},{"key":"1697_CR163","doi-asserted-by":"crossref","unstructured":"Mailankody S, Matous JV, Liedtke M, Sidana S, Malik S, Nath R et al. Universal: an allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed\/refractory multiple myeloma. In: Blood. Amer Soc Hematology 2021 L ST NW, Suite 900, Washington, DC 20036 USA. 2020.","DOI":"10.1182\/blood-2020-140641"},{"issue":"1","key":"1697_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein-Wolterink RG, Wang J, Bos GM, Germeraad WT. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):1\u201335.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1697_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00998-9","volume":"13","author":"A Yilmaz","year":"2020","unstructured":"Yilmaz A, Cui H, Caligiuri MA, Yu J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol. 2020;13(1):1\u201322.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1697_CR166","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbmt.2017.11.022","volume":"24","author":"RL Williams","year":"2018","unstructured":"Williams RL, Cooley S, Bachanova V, Blazar BR, Weisdorf DJ, Miller JS, et al. Recipient T Cell exhaustion and successful adoptive transfer of haploidentical natural killer cells. Biol Blood Marrow Transplant. 2018;24(3):618\u201322.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1697_CR167","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/j.clml.2019.09.036","volume":"19","author":"EM Mart\u00edn","year":"2019","unstructured":"Mart\u00edn EM, Encinas J, Garc\u00eda-Ortiz A, Ugalde L, Fern\u00e1ndez RA, Leivas A, et al. Exploring NKG2D and BCMA-CAR NK-92 for adoptive cellular therapy to multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19(10):e24\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"1697_CR168","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1697_CR169","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","volume":"22","author":"HM Zarour","year":"2016","unstructured":"Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 2016;22(8):1856\u201364.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1697_CR170","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","volume":"4","author":"DJ Chung","year":"2016","unstructured":"Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4(1):61\u201371.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1697_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9(1):1\u201312.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1697_CR172","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4\u20131BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581\u201390.","journal-title":"Nat Med"},{"issue":"1","key":"1697_CR173","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Mukherjee M, Srinivasan M, Krenciute G, Dakhova O, Zheng Y, et al. Tonic 4\u20131BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 2017;21(1):17\u201326.","journal-title":"Cell Rep"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01697-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01697-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01697-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T08:08:15Z","timestamp":1666426095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01697-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":173,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1697"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01697-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"3 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BP reports personal fees from AbbVie, personal fees from Amgen, stock ownership from BMS, personal fees from Genentech, personal fees from Janssen, and personal fees from Regeneron, outside the submitted work. CR reports personal fees from Amgen, personal fees from BMS, personal fees from Janssen, personal fees from Karyopharm, personal fees from Oncopeptides, and personal fees from Janssen, outside the submitted work. SZU reports research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda and personal fees (consulting) from AbbVie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, and TeneoBio.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed equally to the design, authorship, and revision of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}